Holistic Integrative Pharmacy Institutes, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Holistic Integrative Pharmacy Institutes, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Biomed Pharmacother. 2020 Jul;127:110098. doi: 10.1016/j.biopha.2020.110098. Epub 2020 Apr 13.
N-methyladenosine (mA) is the most abundant RNA modification; mA modifications are installed by methyltransferases, removed by demethylases and recognized by reader proteins. MA plays crucial roles in a variety of biological processes by regulating target RNA translation, splicing, nuclear export, and decay. Since the establishment of methylated RNA immunoprecipitation-sequencing methodology, over three hundred articles about mA modulators, including "writers", "erasers" and "readers", have been reported in the last four years. In addition, an increasing number of molecular mechanisms underlying mA RNA methylation in human cancers have been comprehensively clarified. The recently emerged molecular mechanisms of mA modulators in cancer cell proliferation, cell cycle progression, migration and invasion, apoptosis, and autophagy remain to be summarized. Hence, this review specifically summarizes these recent advances in the understanding of mA molecular mechanisms in tumorigenesis and cancer progression. In addition, we discuss the prospect of using an mA methylation modulator as a new diagnostic biomarker and therapeutic target for human cancers.
N6-甲基腺苷(m6A)是最丰富的 RNA 修饰;m6A 修饰由甲基转移酶进行安装,由去甲基酶进行去除,并被阅读器蛋白识别。MA 通过调节靶 RNA 翻译、剪接、核输出和降解,在多种生物学过程中发挥关键作用。自建立甲基化 RNA 免疫沉淀测序方法以来,在过去四年中已经报道了超过 300 篇关于 m6A 调节剂的文章,包括“writers”、“erasers”和“readers”。此外,越来越多的人类癌症中 m6A RNA 甲基化的分子机制已被全面阐明。m6A 调节剂在癌细胞增殖、细胞周期进程、迁移和侵袭、细胞凋亡和自噬中的分子机制仍有待总结。因此,本综述专门总结了这些关于 m6A 分子机制在肿瘤发生和癌症进展中的最新进展。此外,我们还讨论了将 m6A 甲基化调节剂用作人类癌症新的诊断生物标志物和治疗靶点的前景。